RecruitingPhase 2NCT06492408

Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.

Studying Pediatric hepatocellular carcinoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Principal Investigator
Zhenfeng Zhang, MD, PhD, MD
Second Affiliated Hospital of Guangzhou Medical University
Intervention
ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab(drug)
Enrollment
90 enrolled
Eligibility
18-75 years · All sexes
Timeline
2024 – 2033

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06492408 on ClinicalTrials.gov

Other trials for Pediatric hepatocellular carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Pediatric hepatocellular carcinoma →

← Back to all trials